Acorda Therapeutics, Inc. (ACORQ)

OTCMKTS: ACORQ · Delayed Price · USD
0.130
0.00 (0.00%)
Jul 15, 2024, 1:53 PM EDT - Market open
Market Cap 161.47K
Revenue (ttm) 117.63M
Net Income (ttm) -252.85M
Shares Out 1.24M
EPS (ttm) -203.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,101
Open 0.120
Previous Close 0.130
Day's Range n/a
52-Week Range 0.120 - 18.200
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About ACORQ

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. f... [Read more]

Sector Healthcare
IPO Date Feb 10, 2006
Employees 102
Stock Exchange OTCMKTS
Ticker Symbol ACORQ
Full Company Profile

Financial Performance

In 2023, ACORQ's revenue was $117.63 million, a decrease of -0.79% compared to the previous year's $118.57 million. Losses were -$252.85 million, 283.6% more than in 2022.

Financial numbers in USD Financial Statements

News

Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics

FRANKFURT, Germany--(BUSINESS WIRE)--Merz Therapeutics announces today the successful acquisition of INBRIJA® (levodopa inhalation powder) and (F)AMPYRA® (fampridine), and related assets from Acorda T...

5 days ago - Business Wire

Acorda Therapeutics Announces Delisting from Nasdaq

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Delisting from Nasdaq.

3 months ago - Business Wire

Acorda Therapeutics Announces Nasdaq Delisting Notification

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Nasdaq Delisting Notification.

3 months ago - Business Wire

Acorda Therapeutics shares sink nearly 40% after bankruptcy filing

Shares of Acorda Therapeutics ACOR, +1.96% fell late Monday after the company said it had filed for bankruptcy protection.

3 months ago - Market Watch

Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement.

3 months ago - Business Wire

Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024.

3 months ago - Business Wire

Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024.

3 months ago - Business Wire

Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025.

6 months ago - Business Wire

Acorda Therapeutics Reports Third Quarter 2023 Financial Results

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Third Quarter 2023 Financial Results.

8 months ago - Business Wire

Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023.

8 months ago - Business Wire

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®.

9 months ago - Business Wire

Acorda Therapeutics Reports Second Quarter 2023 Financial Results

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2023 Financial Results.

1 year ago - Business Wire

Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The FightersTM”.

1 year ago - Business Wire

Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023.

1 year ago - Business Wire

Tom Burns Elected to the Acorda Therapeutics Board of Directors

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Tom Burns Elected to the Acorda Therapeutics Board of Directors.

1 year ago - Business Wire

Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement.

1 year ago - Business Wire

Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement.

1 year ago - Business Wire

Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split.

1 year ago - Business Wire

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split.

1 year ago - Business Wire

Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A.

1 year ago - Business Wire

Acorda Therapeutics Reports First Quarter 2023 Financial Results

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports First Quarter 2023 Financial Results.

1 year ago - Business Wire

Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash.

1 year ago - Business Wire

Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China.

1 year ago - Business Wire

Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023.

1 year ago - Business Wire

Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting.

1 year ago - Business Wire